London, United Kingdom, November 18th, 2024. Nanomerics Ltd., a private speciality pharmaceutical company announced that it had received clinical trials authorisation for its first in human OC134 trial from the Medicinal and Healthcare Products Regulatory Agency (MHRA). This means that the trial of OC134 in human subjects may now proceed. OC134 is an eye drop medicine candidate indicated for the topical treatment of moderate to severe allergic conjunctivitis, a condition for which suitable non-steroidal topical ocular treatment does not currently exist. OC134 is powered by Nanomerics’ Molecular Envelope Technology (MET), a non-irritant ocular penetration enhancer.
Professor Ijeoma F. Uchegbu, Nanomerics’ Chief Scientific Officer, of Nanomerics
“This is a remarkable achievement for our company and is testament to the dedication and scientific excellence of the entire Nanomerics’ team involved in the study. We are now able to advance our Molecular Envelope Technology to clinical stage and to complete the first of many clinical studies powered by Nanomerics’ MET, our non-irritant ocular penetration enhancer.”
Nanomerics’ MET is being used to formulate other eye drops such as: OC137, indicated for the treatment of retinal diseases and OC135, indicated for the treatment of glaucoma.